|
|
Title: Preventives and/or
remedies for hyperphosphatemia
United States Patent: 7,087,223
Issued: August 8, 2006
Inventors: Goto; Takeshi
(Tsukuba, JP), Yoshitake; Kazuhisa (Tsukuba, JP), Sorimachi; Hiroshi
(Tsukuba, JP), Moriyama; Kazuteru (Tsukuba, JP)
Assignee: Hisamitsu
Pharmaceutical Co., Inc. (Saga, JP)
Appl. No.: 10/984,149
Filed: November 9, 2004
|
|
|
Training Courses --Pharm/Biotech/etc.
|
Abstract
Provided in a phosphate ion adsorbent
containing a weakly basic anion exchange resin as an active ingredient
which aims at providing preventives and/or remedies for hyperphosphatemia
having a high selectivity for the adsorption of phosphate ion and showing
an effect of lowering blood phosphorus level and another effect of
suppressing phosphorus excretion into the urine.
DISCLOSURE OF THE
INVENTION
The invention is accomplished in view of
the problems of the above prior art, and is to provide a preventive and/or
a remedy for hyperphosphatemia having a high selectivity toward a
phosphate ion adsorption action, further having a lowering action of blood
phosphorus concentration and a lowering action of urinary phosphorus
excretion.
The inventors made extensive researches to solve the above problems and
found out that a weakly basic anion exchange resin, which was only used as
main uses for removal of hydrochloric acid in an aqueous system and a
non-aqueous system, surprisingly has a phosphoric acid adsorption action,
a lowering action of blood phosphoric acid concentration and a lowering
action of urinary phosphorus excretion, and accomplished the invention.
Namely, the invention relates to a phosphate ion adsorbent comprising as
an active ingredient a weakly basic anion exchange resin.
Also, the invention relates to the above phosphate ion adsorbent,
characterized in that the weakly basic anion exchange resin is a copolymer
containing as monomer components an acrylic acid type compound having a
tertiary amino group and divinylbenzene.
Further, the invention relates to the above phosphate ion adsorbent,
characterized in that the copolymer further contains as monomer components
one or more components selected from the group consisting of acrylonitrile,
vinylimidazole, vinylhistidine, vinylpyrazine and diaminodiphenylmethane.
The invention also relates to the above phosphate ion adsorbent,
characterized in that the weakly basic anion exchange resin has porous
bead structure.
Also, the invention relates to the above phosphate ion adsorbent,
characterized in that the weakly basic anion exchange resin is Ionac A-365
(trade name; Sybron Chemicals Co.).
Further, the invention also relates to a preventive and/or a remedy for
hyperphosphatemia, characterized in that it contains the above phosphate
ion adsorbent.
A phosphate ion adsorbent and a preventive and/or a remedy for
hyperphosphatemia according to the invention not only can overcome bad
effects shown in usual weakly basic anion exchange resins and the
aluminum, calcium and magnesium preparations that have been used as a
preventive and/or a remedy for hyperphosphatemia, but also have an
extremely high selectivity toward a phosphorus adsorption action compared
with oral phosphorus adsorbents reported so far in which anion exchange
resins are used.
As described above, considering that in general, a weakly basic anion
exchange resin is a resin that has been used up to now at the industrial
level for the purpose of decoloring, demineralization or hazardous
substance removal for solvent, a supplied water or a waste water, the
effect attained by the invention is totally surprising.
Weakly basic anion exchange resins used in the invention typically have as
its main backbone copolymers of an acrylic acid type compound, which have
a tertiary amino group, for example, such as acrylamide or acrylate, and
divinylbenzene, and further may contain as other monomer components
acrylonitrile, vinylimidazole, vinylhistidine, vinylpyrazine,
diaminodiphenylmethane or the like further in a range that it is
pharmaceutically acceptable and does not reduce the effect. Preferably
they are weakly basic polyacrylate type resins having porous bead
structure.
Although preparation of a weakly basic anion exchange resin used in the
invention can be carried out by a conventional method known by
publications, etc., specifically it can be carried out by copolymerization
of a monovinyl monomer such as acrylic acid or its alkyl ester and
divinylbenzene and reaction of this copolymer with polyalkylene polyamine.
Additionally, this copolymer can be copolymerized with other monomers such
as acrylonitrile, vinylimidazole, vinylhistidine, vinylpyrazine or
diaminodiphenylmethane in a range that it is pharmaceutically acceptable
and does not lose the effect.
Illustrative of such a weakly basic anion exchange resin is, for example,
Ionac A-365 (trade name; Sybron Chemicals Co.) which is being marketed
with the main use for removal of, hydrochloric acid in an aqueous system
and a non-aqueous system.
The phosphoric acid adsorbent and the preventive and/or the remedy for
hyperphosphatemia according to the invention lower blood phosphorus
concentration and urinary phosphorus excretion. Therefore, the preventive
and/or the remedy for hyperphosphatemia according to the invention are
expected to have a preventive and/or therapeutic effect toward a renal
function disorder, chronic renal failure, dialysis, hypocalcemia, excess
secretion of parathyroid hormone (PTH), suppression of vitamin D
activation, ectopic calcification or the like wherein hyperphosphatemia is
considered to be the cause of disease. Further, the preventive and/or
remedy for hyperphosphatemia of the invention are expected to exert a
remarkable preventive effect and/or therapeutic effect toward PTH increase
due to hyperphosphatemia, secondary hyperparathyroidism via vitamin D
lowering, renal osteodystrophy, uremia, central and peripheral nerve
disorders, anemia, myocardial disorders, hyperlipemia, saccharometabolism
disorders, itch, dermal ischemic ulcer, tendon rupture, reproductive
dysfunction, muscle disorder, growth retardation, cardiac conduction
disorders, alveolar diffusion disorders, arteriosclerosis,
immunodeficiency, etc.
Claim 1 of 3 Claims
1. A method of treating
hyperphosphatemia in a patient comprising orally administering to the
patient in need of treatment for hyperphosphatemia a therapeutically
effective amount of a pharmaceutically acceptable phosphate ion absorbent
comprising as an active ingredient a weakly basic anion exchange resin,
wherein said resin is a copolymer containing as monomer components
divinylbenzene and acrylamide or divinylbenzene and acrylate, wherein the
copolymer further contains a tertiary amino group.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|